Boryung-Lilly jointly sell weekly GLP-1 analogue, ‘Trulicity’
On the 7th, Boryung Pharm(CEO Tae-hong Choi) and Lilly Korea(CEO Paul Henry Huibers) announced conclusion of the joint sales agreement for domestic marketing and sales of ‘Trulicity(generic name: dulaglutide),’ a weekly GLP-1(glucagon-like peptide-1) analogue.
Based on the respective marketing ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
